Navigation Links
Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
Date:11/6/2008

BGC 945 Builds Upon a Proven Class of Drugs With Greater Tumor Selectivity

EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has in-licensed a novel targeted oncology compound, BGC 945, from BTG International Limited based in the United Kingdom. Under the terms of the agreement, Onyx will obtain a worldwide license for BGC 945 and all of its related patents. Onyx will receive exclusive worldwide marketing rights and will be responsible for all product development and commercialization activities. BTG will receive a $13 million upfront payment, and payments of up to $72 million upon the attainment of certain global development and regulatory milestones, plus additional milestone payments upon the achievement of certain marketing approvals and commercial milestones. BTG will also receive royalties on future product sales.

"In-licensing a promising compound, such as BGC 945, with potential application in several large tumor markets strategically strengthens Onyx's pipeline and expands our portfolio as a growing biopharmaceutical company," said Tony Coles, M.D., president and chief executive officer of Onyx. "With proven success in developing and commercializing Nexavar as one of the leading targeted oncology therapies, we are well positioned to maximize BGC 945's full potential in a variety of tumors."

BGC 945 (ONX 0801) is designed to work by combining two proven approaches to improving outcomes for cancer patients. These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and division. BGC 945 (ONX 0801) targets malignant cells that overexpress the alpha-folate receptor, which is
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
3. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
6. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
7. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
11. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, has ... independent analysis designed to reflect the healthcare patterns ... This model will be used to characterize the ... could have on those groups of patients and ...
(Date:5/5/2015)... YORK , May 5, 2015 ... announced that Andrew Gengos , President and Chief ... May 7, 2015. DATE:  Thursday, May 7, ... LINK:  http://VirtualInvestorConferences.com > click the red ... be a live, interactive online event where investors ...
(Date:5/5/2015)... D.C., USA (PRWEB) May 05, 2015 ... regulations covering a wide range of key photonics technologies ... hampering global competitiveness of U.S. industry. To help the ... webinar on 12 May on the proposed changes ... the commodities covered by International Traffic in Arms Regulations ...
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing ... - Global Version" report to their offering. ... area of molecular diagnostics and pharmacogenics hold the ... market that is moving out of the national ...
Breaking Biology Technology:RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... , - Books Authored by ... Two of the biggest names in health care publishing, ... agreement to,co-publish International Classification of Diseases, Ninth Revision, Clinical,Modification (ICD-9-CM) ... Buck, beginning with the 2010 editions, in fall 2009. , ...
... Viroblock SA has announced,today that the first ... is active against human influenza. Viroblock,s patented,Cholesterol ... during the extra-cellular phase, by altering and ... The two pre-clinical studies exposed ferrets ...
... Md., March 31 ImQuest Life Sciences today ... of the pyrimidinedione small molecules as antiviral agents ... and Liver Disease meeting held last week in ... ten pyrimidinediones as inhibitors of HBV replication, with ...
Cached Biology Technology:The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books 2The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books 3Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray 2ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C. 2
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Jan. 24, 2011 More than a dozen University ... from robot-assisted surgery techniques to improving heart and breast ... computational surgery Jan. 26-28. The symposium will be held ... Held at the Methodist Institute for ...
... will host its 2011 Biodefense and Emerging Diseases Research ... Hotel in Washington, DC. The purpose of this ... out research to defend against the threat of bioterrorism ... recognizing that emerging infectious diseases serve as a paradigm ...
... important in any relationship, but for spiders, it can be ... male spider needs to convince potentially cannibalistic females that he ... research from the University of Cincinnati shows that male wolf ... increasing their opportunities to successfully mate. To improve the ...
Cached Biology News:Forum to focus on using robotics, imaging and simulation in surgeries 2Forum to focus on using robotics, imaging and simulation in surgeries 3Spiders adjust courtship signals for maximum effect 2Spiders adjust courtship signals for maximum effect 3
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
NNT-1/BSF-3 (N-14)...
Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....
Biology Products: